General Information
|
|
Product
|
Ephrin Receptor A3 Antibody
|
Description
|
Affinity Purified Ephrin Type-A Receptor 3 Antibody
|
Verified Applications
|
ELISA, IP, WB
|
Host
|
Rabbit
|
Species Cross Reactivity
|
Human, Mouse, Rat
|
Immunogen
|
Synthetic peptide taken within amino acid region 900-980 on human EPHA3 protein
|
Physical Properties
|
|
Quantity
|
100 µg
|
Volume
|
200 µl
|
Concentration
|
0.55-0.75 µg/µl in antibody stabilization buffer
|
Form
|
Affinity Purified
|
Clonality
|
Polyclonal
|
Storage
|
-20⁰C for long term storage
|
Application Protocol
|
DB
|
1:10,000
|
ELISA
|
1:10,000
|
Immunoprecipitation |
1:200 |
Western Blot
|
1:500
|
Protein
|
Uniprot #
|
P29320
|
Overview
|
Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling.
|
Molecular Function
|
ATP binding; Nucleotide binding
|
Subcellular Location
|
Isoform 1: Cell membrane; Single-pass type I membrane protein. Isoform 2: Secreted
|
Expression
|
Widely expressed. Highest level in placenta.
|
Structure
|
Heterotetramer upon binding of the ligand. The heterotetramer is composed of an ephrin dimer and a receptor dimer. Oligomerization is probably required to induce biological responses. Forms a ternary EFNA5-EPHA3-ADAM10 complex mediating EFNA5 extracellular domain shedding.
|
Alternative Nomenclature
|
AW492086 antibody
Cek4 antibody
EC 2.7.10.1 antibody
EK4 antibody
End3 antibody
Eph receptor A3 antibody
EPH-like kinase 4 antibody
EPH-like tyrosine kinase 1 antibody
EphA3 antibody
Ephrin type-A receptor 3 antibody
ETK 1 antibody
ETK antibody
HEK 4 antibody
HEK antibody
Human embryo kinase 1 antibody
Mek4 antibody
MGC109882 antibody
Receptor tyrosine kinase HEK antibody
Tyro 4 antibody
Tyrosine-protein kinase TYRO4 antibody
|
|
|